Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains

被引：124

作者：

Sader, HS

Fritsche, TR

Kaniga, K

Ge, YG

Jones, RN

机构：

[1] JMI Labs Inc, N Liberty, IA 52317 USA

[2] Univ Fed Sao Paulo, Sao Paulo, Brazil

[3] Peninsula Pharmaceut, Alameda, CA USA

[4] Tufts Univ, Sch Med, Boston, MA 02111 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2005年 / 49卷 / 08期

关键词：

D O I：

10.1128/AAC.49.8.3501-3512.2005

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

PPI-0903M is a novel N-phosphono-type cephalosporin active against oxacillin-resistant staphylococci and many other gram-positive organisms. This study evaluated the in vitro activity and spectrum of PPI-0903M against 1,478 recent clinical isolates collected from 80 medical centers (22 countries). PPI-0903M demonstrated broader in vitro activity against gram-positive bacteria, particularly against multidrug-resistant staphylococci and streptococci of current clinical concern, than currently available extended-spectrum cephalosporins while maintaining similar activity against gram-negative pathogens.

引用

收藏

页码：3501 / 3512

页数：12

相关论文

共 17 条

[1]

[Anonymous], [No title captured]

[2] Genome and virulence determinants of high virulence community-acquired MRSA [J].

Baba, T ;

Takeuchi, F ;

Kuroda, M ;

Yuzawa, H ;

Aoki, K ;

Oguchi, A ;

Nagai, Y ;

Iwama, N ;

Asano, K ;

Naimi, T ;

Kuroda, H ;

Cui, L ;

Yamamoto, K ;

Hiramatsu, K .

LANCET, 2002, 359 (9320) :1819-1827

[3] In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria [J].

Chamberland, S ;

Blais, J ;

Hoang, M ;

Dinh, C ;

Cotter, D ;

Bond, E ;

Gannon, C ;

Park, C ;

Malouin, F ;

Dudley, MN .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (05) :1422-1430

[4] Increase in community-acquired methicillin-resistant Staphylococcus aureus in children [J].

Frank, AL ;

Marcinak, JF ;

Mangat, PD ;

Schreckenberger, PC .

CLINICAL INFECTIOUS DISEASES, 1999, 29 (04) :935-936

[5] In vitro activity of S-3578, a new broad-spectrum cephalosporin active against methicillin-resistant staphylococci [J].

Fujimura, T ;

Yamano, Y ;

Yoshida, I ;

Shimada, J ;

Kuwahara, S .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (03) :923-931

[6]

Iizawa Yuji, 2004, Journal of Infection and Chemotherapy, V10, P146

[7] TAK-599, a novel N-phosphono type prodrug of Anti-MRSA cephalosporin T-91825:: Synthesis, physicochemical and pharmacological properties [J].

Ishikawa, T ;

Matsunaga, N ;

Tawada, H ;

Kuroda, N ;

Nakayama, Y ;

Ishibashi, Y ;

Tomimoto, M ;

Ikeda, Y ;

Tagawa, Y ;

Iizawa, Y ;

Okonogi, K ;

Hashiguchi, S ;

Miyake, A .

BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (11) :2427-2437

[8] In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci [J].

Jones, RN ;

Deshpande, LM ;

Mutnick, AH ;

Biedenbach, DJ .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (06) :915-932

[9] Bacterial resistance: Origins, epidemiology, and impact [J].

Livermore, DM .

CLINICAL INFECTIOUS DISEASES, 2003, 36 :S11-S23

[10] Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae [J].

Lonks, JR ;

Garau, J ;

Gomez, L ;

Xercavins, M ;

de Echagüen, AO ;

Gareen, IF ;

Reiss, PT ;

Medeiros, AA .

CLINICAL INFECTIOUS DISEASES, 2002, 35 (05) :556-564